Modality
Radioligand
MOA
PARPi
Target
CFTR
Pathway
Innate Imm
RB
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
→ Oct 2028
Phase 1Current
NCT08898328
1,727 pts·RB
2023-02→2028-10·Active
NCT06390739
2,239 pts·RB
2021-07→TBD·Not yet recruiting
3,966 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-162.5y awayInterim· RB
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Not yet…
P1
Active
Catalysts
Interim
2028-10-16 · 2.5y away
RB
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08898328 | Phase 1 | RB | Active | 1727 | EASI-75 |
| NCT06390739 | Phase 1 | RB | Not yet recr... | 2239 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Sovarelsin | BioMarin | Phase 2 | CFTR |